Progyny, Inc.

NasdaqGS:PGNY 주식 보고서

시가총액: US$1.2b

Progyny 관리

관리 기준 확인 4/4

Progyny CEO는 Pete Anevski, Jan2022 에 임명되었습니다 의 임기는 2.83 년입니다. 총 연간 보상은 $ 1.09M, 45.7% 로 구성됩니다. 45.7% 급여 및 54.3% 보너스(회사 주식 및 옵션 포함). 는 $ 2.15M 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 2.15M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 7.7 년입니다.

주요 정보

Pete Anevski

최고 경영자

US$1.1m

총 보상

CEO 급여 비율45.7%
CEO 임기2.8yrs
CEO 소유권0.2%
경영진 평균 재임 기간2.8yrs
이사회 평균 재임 기간7.7yrs

최근 관리 업데이트

Recent updates

Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Nov 21
Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

Nov 18

Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Oct 21
Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny: Poor Year Raises Concerns For Future (Downgrade)

Oct 15

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Sep 29
Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11
Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 20
At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Progyny: Recent Stock Decline Provides Buying Opportunity

Jul 12

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Jun 23
Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Jun 10

Progyny: No Change To Long-Term Outlook

Jun 04

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Apr 29
Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Apr 03
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Mar 15

Progyny: Long-Term Thesis Still Intact

Mar 09

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Mar 01
Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Jan 07
Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Dec 11
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Nov 08
Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Aug 24
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06
There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06
Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25
When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12
Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

CEO 보상 분석

Pete Anevski 의 보수는 Progyny 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

US$57m

Jun 30 2024n/an/a

US$63m

Mar 31 2024n/an/a

US$61m

Dec 31 2023US$1mUS$500k

US$62m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$49m

Mar 31 2023n/an/a

US$43m

Dec 31 2022US$69mUS$500k

US$30m

Sep 30 2022n/an/a

US$42m

Jun 30 2022n/an/a

US$46m

Mar 31 2022n/an/a

US$56m

Dec 31 2021US$786kUS$425k

US$66m

Sep 30 2021n/an/a

US$90m

Jun 30 2021n/an/a

US$78m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$910kUS$425k

US$46m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$5mUS$375k

-US$9m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

US$1m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$682kUS$325k

-US$6m

보상 대 시장: Pete 의 총 보상 ($USD 1.09M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.20M ).

보상과 수익: Pete 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Pete Anevski (57 yo)

2.8yrs

테뉴어

US$1,093,512

보상

Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...


리더십 팀

이름위치테뉴어보상소유권
David Schlanger
Executive Chairman7.7yrsUS$513.57k0.061%
$ 727.2k
Peter Anevski
CEO & Director2.8yrsUS$1.09m0.18%
$ 2.2m
Michael Sturmer
President2.8yrsUS$1.49m0.077%
$ 921.4k
Mark Livingston
Chief Financial Officer4.2yrsUS$1.40m0.052%
$ 621.2k
Allison Swartz
Executive VP2yrsUS$546.22k0.020%
$ 232.5k
Steven Leist
Chief Technology Officerless than a year데이터 없음데이터 없음
James Hart
Vice President of Investor Relationsno data데이터 없음데이터 없음
Risa Fisher
Chief Marketing Officerno data데이터 없음데이터 없음
Cassandra Pratt
Chief Human Resources Officerno data데이터 없음데이터 없음
Julie Stadlbauer
Chief Business Development Officer2.8yrs데이터 없음데이터 없음
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officer1.6yrs데이터 없음데이터 없음
Arielle Bogorad
Senior Vice President of Employer Market Strategy2.5yrs데이터 없음데이터 없음

2.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: PGNY 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
David Schlanger
Executive Chairman7.7yrsUS$513.57k0.061%
$ 727.2k
Peter Anevski
CEO & Director2.8yrsUS$1.09m0.18%
$ 2.2m
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officerno data데이터 없음데이터 없음
Norman Payson
Independent Director7.9yrsUS$567.30k0.48%
$ 5.7m
Fred Cohen
Independent Director9.7yrsUS$583.35k0.014%
$ 169.6k
Beth Seidenberg
Lead Independent Director14.5yrsUS$653.39k0.30%
$ 3.6m
Kevin Gordon
Independent Director5.1yrsUS$518.30k0.0073%
$ 86.7k
Jeffrey Park
Independent Director5.1yrsUS$606.88k0.014%
$ 169.6k
Alan Copperman
Member of the Medical Advisory Boardno data데이터 없음데이터 없음
Barry Behr
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Brad Kolb
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Gerard Letterie
Member of Medical Advisory Boardno data데이터 없음데이터 없음

7.7yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: PGNY 의 이사회경험(평균 재직 기간 7.7 년)으로 간주됩니다.